To satisfy the enablement requirement, you need to include enough examples in the patent specification so others can make and use your invention without excessive trial and error (known as “undue experimentation”). This means providing sufficient examples and explanations to cover the full scope of your claims. Failing to provide enough detail can lead to your patent being considered invalid, as discussed in Amgen Inc. v. Sanofi.
I recommend drafting your specification with sufficient detail to support the broadest possible claims, as achieving broad protection should always be the goal. However, there are times when the inventor may lack the necessary information or test data to fully enable such broad independent claims. While it’s important to aim for broad independent claims, it’s equally important to recognize that these may not always withstand scrutiny. That’s where narrower dependent claims come in.
Craft dependent claims that are closely aligned with the disclosure in the specification. These claims should be unquestionably enabled, ensuring they can survive an invalidity attack by infringers during litigation. By including well-crafted dependent claims, you establish a safety net that ensures enforceable protection even if your broader claims are invalidated. This approach strikes a balance between ambition and practicality, ultimately maximizing the value and enforceability of your patent.
Background: The Amgen v. Sanofi Case
The Amgen v. Sanofi case addressed the enablement requirements for Amgen’s broad genus claims covering antibodies targeting PCSK9, a protein associated with cholesterol regulation. Amgen’s patents claimed antibodies that:
- Bind to specific amino acid residues on the PCSK9 protein, and
- Block PCSK9 from binding to LDL receptors, thereby lowering cholesterol.
To support its genus claim, Amgen provided 26 examples of antibodies that meet these criteria.
However, millions of possible antibodies could potentially function in the same way, far beyond the 26 examples disclosed. Amgen argued that it provided a “roadmap” that would allow skilled practitioners to create other embodiments within the genus without undue experimentation. In contrast, Sanofi contended that this roadmap required excessive trial and error, making it impossible to reproduce the genus without significant additional effort.
Ultimately, the Supreme Court sided with Sanofi, ruling that Amgen’s genus claim was not enabled under 35 U.S.C. § 112(a). This decision set a clear standard: a genus claim must provide enough guidance for others to reproduce the invention’s full scope without undue experimentation.
Key Insights from Amgen: Full-Scope Enablement Requirement
The Amgen ruling brings clarity to the enablement requirement for genus claims, emphasizing that patentees cannot merely provide a few examples or a partial “roadmap” if others must engage in substantial experimentation to reach the invention’s full scope. Here are the core insights from the decision:
- Undue Experimentation Standard Clarified
Building on the “undue experimentation” standard from In re Wands, Amgen specifies that while patentees don’t need to disclose every possible embodiment, they must provide enough information so that a skilled individual in the field can practice the invention across its entire scope without excessive experimentation. A roadmap alone isn’t enough if it leads practitioners to painstaking experimentation. - Implications for High-Variability Fields
Although Amgen deals with biotechnology, it sets a precedent that applies to any field where genus claims are sought. In areas with high variability, such as chemical compositions, software algorithms, and mechanical structures, broad genus claims must be backed by a more extensive disclosure to ensure that others can recreate the full scope without undue experimentation.
Practical Tips for Patent Drafting After Amgen
To strengthen a genus claim post-Amgen, include as many examples as possible to reduce the risk of the written description failing to support the claim’s full scope.
However, even if you don’t have enough examples to fully support the broad genus, it’s still valuable to include the genus claim. Alongside it, include dependent claims directed to specific species or subcategories within the genus. If the genus claim is later found invalid, the strategy is that these narrower species claims may still stand and allow you to sue the infringer.
Need help?
The Amgen v. Sanofi decision highlights the importance of detailed enablement when drafting genus claims, especially to avoid issues with substantial experimentation. If you’re preparing a patent application and want to ensure your claims are fully supported and enforceable, call us at 949-433-0900 to discuss how we can strengthen your patent strategy. Let’s work together to protect your innovations effectively.